scPharmaceuticals Inc. / Fundamentals

    Income statement

    Net revenue
    €42.87M
    Cost of goods sold
    €13.52M
    Gross profit
    €29.35M
    SG&A expenses
    €73.21M
    R&D expenses
    €13.23M
    EBITDA
    -€70.87M
    D&A
    -€33.46K
    EBIT
    -€57.09M
    Interest expenses
    €2.88M
    EBT
    -€78.69M
    Tax expenses
    -€6.63K
    Net income
    -€78.69M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    €22.21M
    Changes in working capital
    -€5.70M
    Operating cash flow
    -€56.51M
    Capex
    €18.02K
    Other investing cash flow
    €0.00
    Net investing cash flow
    -€18.02K
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €46.21M
    Debt repayment
    €0.00
    Other financing cash flow
    €12.41M
    Net financing cash flow
    €58.50M
    Foreign exchange effects
    €0.00
    Net change in cash
    €1.98M
    Cash at end of period
    €35.01M
    Free cash flow
    -€56.49M

    Balance sheet

    Cash and cash equivalents
    €35.01M
    Cash and short-term investments
    €35.01M
    Total receivables
    €16.65M
    Inventory
    €12.50M
    Other current assets
    €3.38M
    Total current assets
    €67.55M
    Property, plant & equipment
    €1.05M
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €259.97K
    Total non-current assets
    €1.31M
    Total assets
    €68.86M
    Accounts payable
    €3.45M
    Short-term debt
    €226.51K
    Other current liabilities
    €13.85M
    Total current liabilities
    €17.53M
    Long-term debt
    €45.62M
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €24.85M
    Total non-current liabilities
    €69.62M
    Total liabilities
    €87.15M
    Common stock
    €4.29K
    Retained earnings
    -€346.86M
    Other equity
    €0.00
    Total equity
    -€18.29M
    Total liabilities and shareholders' equity
    €68.86M

    Company information

    Market capitalization
    €174.26M
    Employees
    162
    Enterprise Value
    €210.20M

    Company ratios

    Gross margin
    68.5% Much better than peer group: -1,201.1%
    EBITDA margin
    -165.3% Much better than peer group: -10,108.5%
    EBIT margin
    -133.2% Much better than peer group: -11,140.7%
    EBT margin
    -183.5% Much better than peer group: -11,060.1%
    Net margin
    -183.5% Much better than peer group: -11,256.1%
    ROE
    430.3% Much better than peer group: -185.3%
    ROA
    -114.3% Much better than peer group: -752.2%
    Asset turnover
    62.3% Much better than peer group: 3.7%
    FCF margin
    -131.8% Much better than peer group: -9,552.9%
    FCF yield
    -32.4%
    Efficiency ratio
    265.3%
    Net sales per employee
    €264.65K
    Net income per employee
    -€485.76K

    Notifications